Sage therapeutics, inc. (SAGE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Total revenue

6,868

90,273

-

-

-

-

-

-

Operating costs and expenses:
Cost of goods sold

400

-

-

-

-

-

-

-

Research and development

368,815

282,107

210,277

120,756

69,357

24,100

14,357

7,229

Selling, general and administrative

345,777

201,404

62,878

39,407

25,293

9,710

3,922

2,402

Total operating costs and expenses

714,992

483,511

273,155

160,163

94,650

33,810

18,279

9,631

Loss from operations

-708,124

-393,238

-273,155

-160,163

-94,650

-33,810

-18,279

-9,631

Interest income, net

27,804

20,334

3,099

1,211

178

8

1

-

Other income, net

82

22

-64

-35

-23

-9

-3

-1

Net loss

-680,238

-372,882

-270,120

-158,987

-94,495

-33,811

-18,281

-9,632

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

2,294

7

4

Net loss attributable to common stockholders

-

-

-

-

-

-36,105

-18,288

-9,636

Net loss per share—basic and diluted

-13.38

-8.08

-7.09

-4.75

-3.40

-1.67

-12.26

-8.62

Weighted average number of common shares outstanding—basic and diluted

50,833

46,121

38,113

33,492

27,778

21,574

1,492

1,118

Comprehensive loss:
Net loss

-680,238

-372,882

-270,120

-158,987

-94,495

-33,811

-18,281

-9,632

Other comprehensive items:
Unrealized gain (loss) on marketable securities

1,810

-486

73

-102

-

-

-

-

Total other comprehensive gain (loss)

1,810

-486

73

-102

-

-

-

-

Total comprehensive loss

-678,428

-373,368

-270,047

-159,089

-94,495

-33,811

-

-

Product Revenue [Member]
Total revenue

3,957

-

-

-

-

-

-

-

Collaboration Revenue [Member]
Total revenue

2,911

90,273

-

-

-

-

-

-